GlassScriptPhysician profile
Timothy A Bella
NPI 1205894995
$9,288.78
in general payments reported to CMS, 2019-2025
47 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $867 · 2021: $1,169 · 2022: $1,432 · 2023: $1,904 · 2024: $1,496 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,104.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,756.30 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,098.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $733.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $642.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $568.08 | 2019-2025 | Repatha, Evenity, Otezla |
| Merck Sharp & Dohme LLC | $506.48 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Glaxosmithkline, LLC. | $413.91 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $345.13 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.79 | 2020-2025 | Trulance, Xifaxan |
| Pfizer INC. | $279.43 | 2019-2025 | |
| Astellas Pharma US INC | $230.46 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $224.49 | 2021-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $189.90 | 2019-2025 | Zoryve |
| Exact Sciences Corporation | $177.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.21 | 2019-2025 | Jardiance |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Bella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.